AGC Biologics, a CDMO, has formed a new Cell and Gene Technologies Division designed to focus and elevate existing AGC Biologics capabilities.

The new AGC Biologics Cell and Gene Technologies Division offers support and scientific ability, backed by a global development and manufacturing network in three regions (Milan, Italy; Longmont, CO, USA; Yokohama, Japan). Furthermore, AGC Biologics’ proprietary cell therapy and viral vector platforms, including ProntoLVV and BravoAAV, offer developers the ability to increase their speed to GMP phases while controlling costs.

The AGC Biologics Milan Cell and Gene Center of Excellence will be the central location for this new Division. The site offers 30 years of experience in cell and gene therapy, with nine commercial approvals and hundreds of GMP batches produced successfully. Its teams of experts have a reputation for collaboration and working side-by-side with customers to find clinical, late-phase, and commercial successes. It holds commercial manufacturing authorizations from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for viral vectors and cell therapies.

The new Cell and Gene Technologies Division features expanded global capabilities, including AGC Biologics’ Longmont facility and the new Yokohama facility, which will begin cell therapy operations in July 2025.

The Cell and Gene Technologies Division offers support for R&D initiatives, solves complexities in clinical stages, builds scalable manufacturing processes, and addresses the unique needs of developers based on the geographical regions they operate in.

Luca Alberici has been appointed Executive Vice President of the Cell and Gene Technologies Division. He will oversee this new Division’s global strategy, operations, and commercial development and will keep his current role as General Manager of the Milan Cell and Gene Center of Excellence.

“Thanks to automation in cell therapy manufacturing, full quality control testing in-house, and a wide facility footprint in each global region, we believe we can now be the partner of choice for most late-stage CGT customers from CAR-T to viral vectors and new trailblazing modalities like exosomes,” said Luca Alberici.

“This dedicated Division will allow us to serve our customers better and support the development of innovative therapies that bring hope to patients worldwide. I look forward to collaborating with our talented teams as we embark on this exciting new chapter,” Alberici added.